Teza Capital Management LLC Has $1.53 Million Stock Position in Pfizer Inc. $PFE

Key Points

• Teza Capital Management LLC significantly reduced its stake in Pfizer Inc. by 59.6% in the first quarter, owning 60,274 shares valued at approximately $1.53 million.
• Pfizer reported $0.78 EPS for the most recent quarter, exceeding estimates and showing a year-over-year revenue increase of 10.3% to $14.65 billion.
• Several analysts updated their price targets for Pfizer, with an average consensus price target of $28.12 and a mix of "neutral", "buy", and "hold" ratings.

Teza Capital Management LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 59.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 60,274 shares of the biopharmaceutical company's stock after selling 88,892 shares during the period. Pfizer makes up 0.7% of Teza Capital Management LLC's portfolio, making the stock its 14th largest position. Teza Capital Management LLC's holdings in Pfizer were worth $1,527,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer in the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 1.3%

Shares of NYSE:PFE opened at $24.86 on Friday. The company's 50-day moving average price is $24.85 and its two-hundred day moving average price is $24.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The stock has a market capitalization of $141.31 billion, a PE ratio of 13.22, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same period in the previous year, the firm posted $0.60 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on PFE shares. Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group boosted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.